| Q37075393 | Apoptotic action of botulinum toxin on masseter muscle in rats: early and late changes in the expression of molecular markers |
| Q82535923 | Botulinum Toxin in Facial Rejuvenation: An Update |
| Q64058189 | Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect |
| Q31084088 | Botulinum toxin A in the mid and lower face and neck |
| Q34620317 | Botulinum toxin type-A in the treatment of glabellar lines. |
| Q36063756 | Botulinum toxins--cause of botulism and systemic diseases? |
| Q27030752 | Comparison and overview of currently available neurotoxins |
| Q35089706 | Exaggeration of wrinkles after botulinum toxin injection for forehead horizontal lines |
| Q39369774 | GDNF overexpression fails to provoke muscle recovery from botulinum toxin poisoning: a preliminary study |
| Q46011540 | Male Surgical Neck Rejuvenation. |
| Q35767092 | Management and prevention of adverse events in esthetic interventions |
| Q33785437 | Repeated injections of botulinum toxin into the masseter muscle induce bony changes in human adults: A longitudinal study |
| Q41649888 | Screening for variations in anterior digastric musculature prior to correction of post-traumatic anterior open bite by injection of botulinum toxin type A: a technical note |
| Q39055083 | Understanding How to Prevent and Treat Adverse Events of Fillers and Neuromodulators |
| Q79972177 | [Aesthetic dermatology. Botulinumtoxin A and soft tissue augmentation] |